Schmerztherapie bei rheumatologischen Erkrankungen

Schlüsselwörter

Schmerztherapie - rheumatoide Arthritis - nichtsteroidale Antirheumatika

Keywords

pain management - rheumatoid arthritis - non-steroidal anti-inflammatory drugs

Literatur

• 1 Baerwald C, Verdecchia P, Duquesroix B. et al . Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study.  Arthritis Rheum. 2010;  62 3635-3644
• 2 Becker G, Blum H. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.  Lancet. 2009;  373 1198-206
• 3 Bolten W. Neubewertung der NSAR im dreistufigen WHO-Schmerztherapie-Schema.  Arthritis Rheuma. 2011;  31 89-98
• 4 Chan F, Lanas A, Scheiman J. et al . Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.  Lancet. 2010;  376 173-179
• 5 Hale M, Upmalis D, Okamoto A. et al . Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.  Curr Med Res Opin. 2009;  25 1095-1104
• 6 Karlsson J, Pivodic A, Aguirre D. et al . Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.  J Rheumatol. 2009;  36 1290-1297
• 7 Laine L, Curtis S, Cryer B. et al . Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34,701 arthritis patients.  Aliment Pharmacol Ther. 2010;  32 1240-1248
• 8 Lane N, Schnitzer T, Birbara C. et al . Tanezumab for the treatment of pain from osteoarthritis of the knee.  N Engl J Med. 2010;  363 1521-1531
• 9 McDougall J. Arthritis and pain. Neurogenic origin of joint pain.  Arthritis Res Ther. 2006;  8 220
• 10 Trelle S, Reichenbach S, Wandel S. et al . Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.  Brit Med J. 2011;  342 c7086
• 11 Van der Linden M, Gaugris S, Kuipers E. et al . COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.  Pharmacoepidemiol Drug Saf. 2009;  18 880-890
• 12 Vauth C, Greiner W. Kosten in der Schmerztherapie.  Gesundh ökon Qual manag. 2011;  16 S3-S9